ArticleThe Journal of allergy and clinical immunology2021
Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients.
Article in The Journal of allergy and clinical immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.British journal of clinical pharmacology · 2026Trial
- Aprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.International journal of molecular sciences · 2024Review
- Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions.International journal of molecular sciences · 2024Review
- Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know.Immunobiology · 2023Review
- Common cold.Frontiers in allergy · 2023Review
- A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases.Molecular biology reports · 2022Review
- Coronavirus disease-19 infection and angioedema in African Americans: A case series.Otolaryngology case reports · 2022Article
- Crosstalk between the renin-angiotensin, complement and kallikrein-kinin systems in inflammation.Nature reviews. Immunology · 2022Review
- Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin BJournal of molecular medicine (Berlin, Germany) · 2022Article
- Mass spectrometric study of variation in kinin peptide profiles in nasal fluids and plasma of adult healthy individuals.Journal of translational medicine · 2022Article
- Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19.Mediators of inflammation · 2022Review
- Immune response induced by novel coronavirus infection.Frontiers in cellular and infection microbiology · 2022Review
- Mechanism deconvolution of Qing Fei Pai Du decoction for treatment of Coronavirus Disease 2019 (COVID-19) by label-free integrative pharmacology assays.Journal of ethnopharmacology · 2021Article
- COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications.Allergy and asthma proceedings · 2021Article
- Targeted LC-MS/MS platform for the comprehensive determination of peptides in the kallikrein-kinin system.Analytical and bioanalytical chemistry · 2021Article
- SARS-CoV-2 Exacerbates COVID-19 Pathology Through Activation of the Complement and Kinin Systems.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.